Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kathy Cutter"'
Autor:
Susan Blumel, R. Gregory Bociek, Kathy Cutter, Emily K. Pauli, Julie M. Vose, Michael S. Weiss, Hari P. Miskin, Philip J. Bierman, Matthew A. Lunning, Jonathon B. Cohen, Tanya Siddiqi, Peter Sportelli, Marshall T. Schreeder, Christopher R. Flowers
Publikováno v:
Blood. 132:4197-4197
Introduction: Umbralisib (UMB) is a next generation, once daily, PI3Kδ/CK1ε inhibitor, active in patients with relapsed or refractory (rel/ref) hematologic malignancies that, in long-term follow-up, has demonstrated a uniquely differentiated safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60e052d5b83d193ab69748c723a73f1a
https://doi.org/10.1182/blood-2018-99-118917
https://doi.org/10.1182/blood-2018-99-118917
Autor:
Kathy Cutter, Marshall T. Schreeder, Robert O. Dillman, Elizabeth F. Connelly, Carol DePriest, Jeremy K. Hon
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 22:185-193
We conducted a multicenter, community-based phase II trial of PCR biochemotherapy (pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2) every 3 weeks for up to 6 cycles in patients with chronic lymphocytic leukemia (CLL) or small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea8092f52c2e9f7436523c295981d46
https://doi.org/10.1089/cbr.2007.332
https://doi.org/10.1089/cbr.2007.332
Autor:
Kathy Cutter, Michael S. Weiss, Hari P. Miskin, Susan Blumel, R. Gregory Bociek, Peter Sportelli, Marshall T. Schreeder, Julie M. Vose, Emily K. Pauli, Matthew A. Lunning, Philip J. Bierman
Publikováno v:
Blood. 128:4197-4197
Introduction: Ublituximab (UTX) is a novel glycoengineered mAb targeting a unique epitope on the CD20 antigen. TGR-1202 is a next generation, once daily, PI3Kδ inhibitor, active in patients (pts) with rel/ref hematologic malignancies that has demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a53cbda7bf66e833a206557d00dcb54
https://doi.org/10.1182/blood.v128.22.4197.4197
https://doi.org/10.1182/blood.v128.22.4197.4197
Autor:
Marshall T. Schreeder, Peter Sportelli, Lee Ann Dietz, Daruka Mahadevan, Emily K. Pauli, Kathy Cutter, Hari P. Miskin
Publikováno v:
Blood. 126:2942-2942
Introduction: TGR-1202 is a next generation, once daily, oral PI3Kδ inhibitor that displays promising clinical activity in patients with relapsed and refractory hematologic malignancies, with a differentiated safety and tolerability profile compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96d4a60e2699cff06c8b92e204c817be
https://doi.org/10.1182/blood.v126.23.2942.2942
https://doi.org/10.1182/blood.v126.23.2942.2942
Autor:
Peter Sportelli, Susan Blumel, Ryan Handy, Loretta J. Nastoupil, Kathy Cutter, Matthew A. Lunning, Marshall T. Schreeder, William G. Wierda, Myra Miguel, Hari P. Miskin, Jonathon B. Cohen, Julie M. Vose, Michael S. Weiss, Susan O'Brien, Jan A. Burger, Christopher R. Flowers, Nathan Fowler, Emily K. Pauli, Tanya Siddiqi
Publikováno v:
Blood. 126:1538-1538
Introduction: Ublituximab (UTX) is a novel anti-CD20 mAb that has been glycoengineered for enhanced ADCC. TGR-1202 is a novel once daily oral PI3Kδ inhibitor with clinical activity in B-cell lymphoma and a notably differentiated tolerability profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c220bf7f2397ca198962e968994c74c3
https://doi.org/10.1182/blood.v126.23.1538.1538
https://doi.org/10.1182/blood.v126.23.1538.1538
Autor:
Matthew A. Lunning, Susan Blumel, Srikant Viswanadha, Nathan Fowler, Warner H Tse, Emily K. Pauli, Myra Miguel, Peter Sportelli, Jonathon B. Cohen, Kathy Cutter, Michael S. Weiss, Marshall T. Schreeder, Julie M. Vose, Susan O'Brien, Hari P. Miskin, Tanya Siddiqi, Swaroop Kumar Venkata Satya Vakkalanka, Loretta J. Nastoupil, Christopher R. Flowers
Publikováno v:
Journal of Clinical Oncology. 33:8548-8548
8548 Background: Ublituximab (UTX) is a novel glycoengineered anti-CD20 mAb. TGR-1202 is a novel once daily oral PI3Kδ inhibitor. UTX + TGR-1202 has shown strong synergistic activity in-vitro (Luga...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9264951f24808b87d26ad26bc557663
https://doi.org/10.1200/jco.2015.33.15_suppl.8548
https://doi.org/10.1200/jco.2015.33.15_suppl.8548
Autor:
Kathy Cutter, Marshall T. Schreeder, Hari P. Miskin, Michael S. Weiss, Warner H Tse, Loretta J. Nastoupil, Brianna Phye, Jonathon B. Cohen, Swaroop Kumar Venkata Satya Vakkalanka, Julie M. Vose, Myra Miguel, Susan O'Brien, Susan Blumel, Tanya Siddiqi, Matthew A. Lunning, Christopher R. Flowers, Srikant Viswanadha, Peter Sportelli, Nathan Fowler, Emily K. Pauli
Publikováno v:
Journal of Clinical Oncology. 33:8501-8501
8501 Background: Multiple novel targeted agents are emerging for B-cell malignancies, but few studies have successfully and safely combined these agents. Ublituximab (UTX) is a novel glycoengineere...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8bab46ebfffd8a1cc8494460e6dafe5
https://doi.org/10.1200/jco.2015.33.15_suppl.8501
https://doi.org/10.1200/jco.2015.33.15_suppl.8501
Autor:
Hari P. Miskin, Michael S. Weiss, Tanya Siddiqi, Matthew A. Lunning, Marshall T. Schreeder, Warner H Tse, Srikant Viswanadha, Peter Sportelli, Susan O'Brien, Swaroop Vakkalanka, Susan Blumel, Nathan Fowler, Emily K. Pauli, Julie M. Vose, Loretta J. Nastoupil, Kathy Cutter
Publikováno v:
Blood. 124:801-801
Introduction: Ublituximab (UTX) is a novel chimeric mAb targeting a unique epitope on the CD20 antigen, glycoengineered to enhance affinity to FcγRIIIa receptors, thereby demonstrating significantly greater ADCC than rituximab. UTX monotherapy in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::581580d26c6aef4a10fa94730b7710b3
https://doi.org/10.1182/blood.v124.21.801.801
https://doi.org/10.1182/blood.v124.21.801.801
Autor:
Marnie Brotherton, Michelle Ann Mackenzie, Jamie Hodgson, Mazen Khalil, Marshall T. Schreeder, Charles M. Farber, Molly Patterson, Kathy Cutter, Owen A. O'Connor, Hari P. Miskin, Changchun Deng, Jasmine M. Zain, Peter Sportelli, Amber Moon, Emily K. Pauli, Petros Nikolinakos, Jennifer E Amengual, Christen N Cooper, Ahmed Sawas, Daruka Mahadevan
Publikováno v:
Journal of Clinical Oncology. 32:8524-8524
8524 Background: Ublituximab (UTX) is a novel mAb targeting a unique epitope on the CD20 antigen, glycoengineered for greater ADCC than rituximab (RTX). A prior Phase I/Ib trial with UTX monotherap...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fcce9fb125b0fca627ab4b21a6d8e0e
https://doi.org/10.1200/jco.2014.32.15_suppl.8524
https://doi.org/10.1200/jco.2014.32.15_suppl.8524
Autor:
Robert O. Dillman, Marshall T. Schreeder, Jeremy K. Hon, Elizabeth F. Connelly, Carol DePriest, Kathy Cutter
Publikováno v:
Cancer Biotherapy & Radiopharmaceuticals; Apr2007, Vol. 22 Issue 2, p185-193, 9p